嵌合抗原受体治疗多发性骨髓瘤

icartab

Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.

The introduction of chimeric antigen receptor (CAR)-modified T cells has revolutionized immunotherapy and cancer treatment as a whole. However, so far, clinical efficacy has only been demonstrated for CD19-positive B cell lymphomas. For Multiple Myeloma (MM), the second most common haematological malignancy, there are currently no clinical results supporting the usefulness of the adoptive transfer of CAR-modified T cells.

This might be related to the fact that an ideal surface target has not yet been identified or the presence of strong local immunosuppression in the tumour microenvironment, which is a hallmark of MM. In this review, we provide a comprehensive overview of promising target molecules for CAR T cell approaches in MM and we outline a number of ways in which the local immunosuppression in MM can be overcome. By providing a strategy for the design of CAR T cell treatments for MM we hope to transform this new therapeutic approach into a valuable tool within the therapeutic armamentarium for MM.

嵌合抗原受体治疗多发性骨髓瘤

嵌合抗原受体修饰的T细胞疗法已经对免疫治疗和癌症治疗产生了整体的变革。然而，到目前为止，临床有效性仅仅在CD19靶向B细胞淋巴细胞癌的治疗中有明确的效果。对于多发性骨髓瘤（MM），第二个最普遍的恶性血液肿瘤，还没有临床试验结果说明利用CAR-T 过继T细胞治疗有明显的治疗效果。这有可能与还没有发现一个理想的表面标记物或者在免疫微环境中存在的强大的免疫抑制有关联。在这篇综述中，我们全面回顾了靶向MM疾病的CAR-T的分子，并且列出了克服MM局部免疫抑制环境的一些方法。通过设计CAR-T细胞的方案，我们希望将这种新技术成为一种有效治疗MM的工具。

出自爱康得生物技术